Bamco Inc. NY Increases Stock Position in BioNTech SE (NASDAQ:BNTX)

Bamco Inc. NY raised its holdings in BioNTech SE (NASDAQ:BNTX) by 3.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 251,223 shares of the company’s stock after acquiring an additional 8,875 shares during the quarter. Bamco Inc. NY’s holdings in BioNTech were worth $23,175,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Baillie Gifford & Co. increased its position in shares of BioNTech by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after buying an additional 86,343 shares in the last quarter. Primecap Management Co. CA increased its position in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after purchasing an additional 131,490 shares in the last quarter. Harding Loevner LP purchased a new stake in BioNTech during the 4th quarter worth about $410,984,000. Flossbach Von Storch AG increased its position in BioNTech by 1.0% during the 4th quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after purchasing an additional 35,445 shares in the last quarter. Finally, Capital World Investors increased its position in BioNTech by 0.5% during the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock worth $87,002,000 after purchasing an additional 4,369 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the subject of several recent analyst reports. TD Cowen lifted their price target on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. HC Wainwright restated a “buy” rating and issued a $113.00 price target on shares of BioNTech in a report on Wednesday, June 26th. Evercore ISI initiated coverage on BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target for the company. Finally, BMO Capital Markets lowered their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, BioNTech presently has an average rating of “Hold” and an average target price of $111.70.

BioNTech Trading Up 1.5 %

Shares of NASDAQ BNTX traded up $1.26 during midday trading on Friday, hitting $85.94. The stock had a trading volume of 265,280 shares, compared to its average volume of 510,937. The company has a market capitalization of $20.43 billion, a price-to-earnings ratio of 171.88 and a beta of 0.23. BioNTech SE has a 1-year low of $78.02 and a 1-year high of $125.83. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $89.32 and a 200 day moving average price of $91.37.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The firm had revenue of $203.69 million during the quarter, compared to analyst estimates of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. On average, analysts predict that BioNTech SE will post -2 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.